Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period. Adhera Therapeutics's Dividend Payout Ratio for the
months ended in Sep. 2023 was 0.00.
The historical rank and industry rank for Adhera Therapeutics's Dividend Payout Ratio or its related term are showing as below:
ATRX's Dividend Payout Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 0.43 * Ranked among companies with meaningful Dividend Payout Ratio only.
Adhera Therapeutics (OTCPK:ATRX) Dividend Payout Ratio Explanation
In dividends investing, Dividend Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Adhera Therapeutics Dividend Payout Ratio Related Terms
Adhera Therapeutics Dividend Payout Ratio Historical Data
* Premium members only.
The historical data trend for Adhera Therapeutics's Dividend Payout Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ATRX vs PKBO, ARDS, NYMXF: Dividend Payout Ratio Comparison
For the Biotechnology subindustry, Adhera Therapeutics's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adhera Therapeutics Dividend Payout Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adhera Therapeutics's Dividend Payout Ratio distribution charts can be found below:
* The bar in red indicates where Adhera Therapeutics's Dividend Payout Ratio falls into.
Adhera Therapeutics Dividend Payout Ratio Calculation
The Dividend Payout Ratio is the measure of dividends paid out to shareholders relative to the company's net income. It is calculated as the Dividends per Share divided by the Earnings per Share (Diluted) during the same time period.
Adhera Therapeutics's Dividend Payout Ratio for the fiscal year that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adhera Therapeutics (ATRX) has a Dividend Payout Ratio of 0.00 as of Sep. 2023. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Adhera Therapeutics and its competitors.
Is Adhera Therapeutics' Dividend Payout Ratio too high?
Adhera Therapeutics' current Dividend Payout Ratio is 0.00. Overall, Adhera Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Adhera Therapeutics' Dividend Payout Ratio compare to PKBO and ARDS?
Adhera Therapeutics' Dividend Payout Ratio of 0.00 can be compared against companies in the Biotechnology industry. The industry median Dividend Payout Ratio is 0.43. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Payout Ratio for a Biotechnology company?
The median Dividend Payout Ratio among Biotechnology companies is 0.43, based on 130 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Payout Ratio significantly above this median, while those in the bottom quartile fall well below. However, Dividend Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Payout Ratio mean?
A high Dividend Payout Ratio can signal that a stock is expensive relative to its fundamentals. Dividend payout ratio is the percent of company earnings paid out as dividends. View historical data on Adhera Therapeutics and its competitors. For the Biotechnology industry, the median Dividend Payout Ratio is 0.43 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adhera Therapeutics's current Dividend Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adhera Therapeutics stock overvalued right now?
Adhera Therapeutics (ATRX) has a current Dividend Payout Ratio of 0.00. The current Dividend Payout Ratio is 0.00. Adhera Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Payout Ratio calculated?
Dividend Payout Ratio is calculated from a company's financial statements. For Adhera Therapeutics (ATRX), the current Dividend Payout Ratio is 0.00 as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Adhera Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing advanced drug candidates through accelerated pathways. The company's pipeline includes MLR-1019 for Parkinson's disease and MLR-1023 for diabetes, both licensed from the Melior Discovery group. MLR-1019 (armesocarb) is a drug candidate targeting both movement and non-movement symptoms of Parkinson's disease, while MLR-1023 (tolimidone) is being developed for Type 1 diabetes and has undergone Phase 2a and 2b studies in Type 2 diabetes patients. It also explores additional drug development opportunities and maintains legacy assets such as CEQ508, an oral RNA therapy candidate for polyps associated with Familial Adenomatous Polyposis (FAP).
12GF Score
Get the complete analysis for ATRX
Dividend Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATRX has been successfully added to your 
